171 related articles for article (PubMed ID: 14625878)
1. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers.
Zwanzger P; Eser D; Padberg F; Baghai TC; Schule C; Rötzer F; Ella R; Möller HJ; Rupprecht R
Depress Anxiety; 2003; 18(3):140-3. PubMed ID: 14625878
[TBL] [Abstract][Full Text] [Related]
2. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder.
Zwanzger P; Eser D; Nothdurfter C; Baghai TC; Möller HJ; Padberg F; Rupprecht R
Pharmacopsychiatry; 2009 Nov; 42(6):266-9. PubMed ID: 19924586
[TBL] [Abstract][Full Text] [Related]
3. Changes in CCK-4 induced panic after treatment with the GABA-reuptake inhibitor tiagabine are associated with an increase in 3alpha,5alpha-tetrahydrodeoxycorticosterone concentrations.
Zwanzger P; Eser D; Romeo E; di Michele F; Baghai TC; Pasini A; Padberg F; Rupprecht R
Psychoneuroendocrinology; 2009 Nov; 34(10):1586-9. PubMed ID: 19501468
[TBL] [Abstract][Full Text] [Related]
4. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.
Zwanzger P; Baghai TC; Schuele C; Ströhle A; Padberg F; Kathmann N; Schwarz M; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2001 Nov; 25(5):699-703. PubMed ID: 11682253
[TBL] [Abstract][Full Text] [Related]
5. Tiagabine in anxiety disorders.
Schwartz TL; Nihalani N
Expert Opin Pharmacother; 2006 Oct; 7(14):1977-87. PubMed ID: 17020423
[TBL] [Abstract][Full Text] [Related]
6. Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice.
Thoeringer CK; Erhardt A; Sillaber I; Mueller MB; Ohl F; Holsboer F; Keck ME
J Psychopharmacol; 2010 May; 24(5):733-43. PubMed ID: 19346277
[TBL] [Abstract][Full Text] [Related]
7. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.
Zwanzger P; Rupprecht R
J Psychiatry Neurosci; 2005 May; 30(3):167-75. PubMed ID: 15944741
[TBL] [Abstract][Full Text] [Related]
8. The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects.
Ströhle A; Graetz B; Scheel M; Wittmann A; Feller C; Heinz A; Dimeo F
J Psychiatr Res; 2009 Aug; 43(12):1013-7. PubMed ID: 19289240
[TBL] [Abstract][Full Text] [Related]
9. Saccadic eye velocity after selective GABAergic treatment with tiagabine in healthy volunteers.
Zwanzger P; Schule C; Eser D; Baghai TC; Padberg F; Ella R; Moller HJ; Rupprecht R; Kathmann N
Neuropsychobiology; 2005; 52(3):147-50. PubMed ID: 16127281
[TBL] [Abstract][Full Text] [Related]
10. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
Pollack MH; Tiller J; Xie F; Trivedi MH
J Clin Psychopharmacol; 2008 Jun; 28(3):308-16. PubMed ID: 18480688
[TBL] [Abstract][Full Text] [Related]
11. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
Zwanzger P; Eser D; Aicher S; Schüle C; Baghai TC; Padberg F; Ella R; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707
[TBL] [Abstract][Full Text] [Related]
12. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
Schunck T; Mathis A; Erb G; Namer IJ; Hode Y; Demazières A; Luthringer R
J Psychopharmacol; 2011 Jan; 25(1):52-9. PubMed ID: 20498136
[TBL] [Abstract][Full Text] [Related]
13. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity to cholecystokinin-tetrapeptide in major depression.
Koszycki D; Copen J; Bradwejn J
J Affect Disord; 2004 Jun; 80(2-3):285-90. PubMed ID: 15207943
[TBL] [Abstract][Full Text] [Related]
15. An open-label study of tiagabine in panic disorder.
Sheehan DV; Sheehan KH; Raj BA; Janavs J
Psychopharmacol Bull; 2007; 40(3):32-40. PubMed ID: 18007567
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical studies with the GABAergic compounds vigabatrin and tiagabine.
Sills GJ
Epileptic Disord; 2003 Mar; 5(1):51-6. PubMed ID: 12773297
[TBL] [Abstract][Full Text] [Related]
17. Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4.
Eser D; Leicht G; Baghai T; Pogarell O; Schüle C; Karch S; Nothdurfter C; Rupprecht R; Mulert C
J Psychiatr Res; 2009 Jan; 43(4):393-400. PubMed ID: 18534623
[TBL] [Abstract][Full Text] [Related]
18. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
Dhir A; Akula KK; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):835-43. PubMed ID: 18234412
[TBL] [Abstract][Full Text] [Related]
19. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers.
Koszycki D; Zacharko RM; Le Mellédo JM; Bradwejn J
Depress Anxiety; 1998; 8(1):1-7. PubMed ID: 9750972
[TBL] [Abstract][Full Text] [Related]
20. Panic induction with cholecystokinin-tetrapeptide (CCK-4) Increases plasma concentrations of the neuroactive steroid 3alpha, 5alpha tetrahydrodeoxycorticosterone (3alpha, 5alpha-THDOC) in healthy volunteers.
Eser D; di Michele F; Zwanzger P; Pasini A; Baghai TC; Schüle C; Rupprecht R; Romeo E
Neuropsychopharmacology; 2005 Jan; 30(1):192-5. PubMed ID: 15467707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
